Rhophylac Unapproved Use Claims Targeted In CBER Untitled Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
ZLB Behring is falsely promoting an unapproved indication for the immune globulin product in an American Hospital Formulary Service fact sheet, FDA says.